Seventy consecutive patients presenting with a clinical diagnosis of chronic muscle contraction headache over a two-year period were evaluated for depression and anxiety scores, along with other possible aetiological factors in this form of headache. Fifty-five of these patients (33 from a hospital neurology clinic and 22from a local general practice) completed a double-blind study to evaluate flupenthixol 0.5 rng twice daily, diazepam 5 mg twice daily and placebo as prophylactic agents.
Introduction
Chronic muscle contraction headache is one of the commonest symptoms presenting in general practice. The average family physician would expect about 25 new cases per year and a consultant neurologist 40. The problem occurs mainly in patients under 45 and is approximately three times more common in women than in men I.
Depression in these patients is being noted increasingly frequently2.3, although few observers have measured it objectively. Headache is common in depression and may be the only presenting symptom. Anxiety may also occur in both groups and the severity is often increased by concern over a possible sinister cause of the headache. Antidepressantst" and anxiolytics have been found to be useful in relieving both simple muscle contraction headache and headache presenting as a symptom of depression.
Flupenthixol, a neuroleptic drug of the thioxanthene group, was introduced in Scandinavia in the treatment of schizoph..·enia and other psychotic illnesses. Its use in small doses as an antidepressant was reported in 1965 6 • The drug characteristically produced an early clinical response, without giving rise to habituation, abstinence symptoms 7 or similar side effects. In one study, 86% of depressed patients noted an improvement in headaches. In the present study the effect offlupenthixol on patients presenting with chronic muscle contraction headaches was compared with diazepam, an established though not ideal agent, in a placebo controlled double-blind crossover trial.
Patients
Seventy patients with a clinical diagnosis of chronic muscle contraction headache were invited to enter the study. They comprised 2 groups: 30 consecutive cases presenting in a modern rural general practice (Group A); and 40 consecutive patients referred to a consultant neurologst (Group B). In all patients the diagnosis had to be agreed by two physicians, who in Group A were the general practitioner at the first consultation and the research fellow, and in Group B the consultant neurologist and research fellow. The definition of headache was in accordance with the Ad Hoc Committee classification9:'Ache or sensation of tightness, pressure or constriction widely varied in intensity, frequency and duration, sometimes longlasting and commonly suboccipital. It is associated with sustained contraction of skeletal muscles in the absence of permanent structural change, usually as a part of an individual's reaction during life stress.'
The age limits were 18-55 years, because of the likelihood of coexisting pathology in an older group. Patients were excluded from the study where there was doubt over clinical diagnosis because of migraine, cervical spondylosis, sinusitis, dental pain, refractive eye problems, severe systemic illness, hypertension and pregnancy. Patients currently taking antidepressants, anxiolytics, antihypertensives, hypnotics or treated with such drugs within the last 2 years were also excluded. The taking of oral contraceptives was noted. As the role of hypertension in headache is controversial I 0, it was decided that hypertensive patients should not be included.
Methods
On admission to the study a detailed history of headaches was taken and a full clinical examination was carried out by the same research fellow throughout. In addition, the following psychological tests were performed initially and after each treatment period: (a) Hamilton depression/anxiety scale; and (b) visual analogue scales for depression and anxiety.
The trial design was that of a double-blind crossover randomized study with 3 treatment periods of 6 weeks preceded by an initial 2-week run-in period. The three treatments consisted of: (1) one placebo tablet twice daily (matched); (2) one diazepam tablet 5 mg twice daily (matched); (3)one flupenthixol tablet 0.5 mg twice daily (matched).
Patients were followed up after each 6-week treatment period using the same psychological tests as on admission. They were also required to keep a headache diary card, recording (1) 
Possible exacerbating factors
We were unable to detect an abnormally high consumption of alcohol or coffee and there was no obvious relationship between oral contraceptives and headaches or any detectable link with menstrual periods. Only 2 of the 50 women showed obvious premenstrual association of headaches: one responded significantly to flupenthixol, whereas the other showed no response to any of the 3 treatments. Chronic muscle contraction headache was a very rare cause of time lost from work, only 2 patients losing more than one week per year and 5 losing the occasional day. All these patients were female. 690 Journal of the Royal Society of Medicine Volume 80 November 1987 with headache; (2) severity on a scale of 0-4, where O=none, l=mild, 2=moderate, 3=severe, 4=very severe; (3) analgesic consumption (cross-checked by tablet counts; soluble aspirin BP or paracetamol BP was provided unless patients specified an alternative preference); (4)side effects; (5) time lost from work or inability to perform daily duties because of headache. Criteria for withdrawal included pregnancy, development of severe symptoms or intercurrent illness assessed by either physician as making it in the patient's best interests to discontinue the trial and instigate further medical action.
Data were analysed using a one-way analysis of variance with repeated measures and Tukey Post Hoc test.
Results
Seventy patients entered the study, 30 in Group A and 40 in Group B. Three patients were lost to follow up after the first treatment period had commenced and ignored subsequent correspondence. There were a further 12 withdrawals during the subsequent 18 weeks of treatment: 3 suffered worsening depression requiring tricyclic antidepressant treatment (one subsequently requiring urgent psychiatric admission); 3 exhibited intolerance of diazepam, mainly dizziness or drowsiness; 2 had 'second thoughts', deciding they would rather not take drugs; one suffered placebo 'side effects' (probably representing a withdrawal state from the preceding diazepam treatment on which she had improved, but she was disorientated and requested withdrawal); one became pregnant; one developed biliary colic; and one was admitted for investigation of nonspecific abdominal pain.
Comparison between general practice and hospital groups
Patients attending the hospital neurology clinic (Group B) had more headaches (P<O.Ol), higher analgesic consumption (P<O.01) and three times longer headache history (Table 1) . They were more depressed as measured by the Hamilton depression scale (P<O.Ol), but no more anxious as measured by the anxiety visual analogue scale (P<0.05). 
Comparison between treatments
Placebo produced no effect on the number of days with headache ( Figure 1 ). Both diazepam and flupenthixol lowered the number of headache days compared with pretreatment and placebo (P<O.Ol for both active drugs). The mean analgesic consumption pretreatment of 106.1 tablets per 42 days was reduced to 77.9 on placebo (P<O.01), 54.2 on diazepam (P<O.01), and 49.7 on flupenthixol (P<O.Ol). Compared with placebo, the effect of diazepam was significant at the P<0.05 level, whereas flupenthixol reached P<O.01 (Figure 2) . Flupenthixol had agreatereffect than either diazepam or placebo in reducing the Hamilton depression score (P < 0.01 for pre-test and P < 0.05 over diazepam and placebo). There was a slight trend for diazepam to worsen the Hamilton depression score but this was not significant.
All three drugs improved the anxiety visual analogue scale (P<O.Ol) but the variance between trials (24.75) and between subjects (22.71) in the Tukey Post Hoc Test was above the desired level for critical evaluation.
There was no relationship between improvement in depression and improvement in headache or analgesic consumption with f1upenthixol, suggesting an effect unrelated to its antidepressant action.
No difference in the therapeutic response in groups A and B was found, despite the greater severity in headache and depression noted in group B prior to treatment.
Discussion
Depression has been identified as an associated feature of chronic recurrent headaches II. The causal relationship between muscle contraction headache and depression has remained controversial. Weatherhead I 2 focused on depression as the cause of headache whereas Martinl ' considered depression to be secondary to headache. Our evidence supports the latter view, as an initial mean Hamilton score of 13.9 is not compatible with a diagnosis of clinical depression. The higher scores in patients with a longer duration of symptoms suggests that depression worsens with time and increases the likelihood for specialist referral.
The key to successful management of chronic recurrent headache is correct diagnosis. The importance of detailed headache history, detailed general medical, psychological, emotional and family histories and the importance of proper physical and neurological examination must be stressed. In the majority of cases, this is all that is needed to establish the diagnosis of chronic muscle contraction headache. Fitzpatrick and Hopkins!" pointed out that a well motivated primary physician may influence the process of patient reassurance as effectively as the consultant neurologist, and also that extensive laboratory and radiological investigations are rarely indicated purely to provide additional reinforcement. We found the headache diary cards invaluable for evaluation of severity and assessment of follow up. They are particularly valuable in the assessment of analgesic consumption and will help to identify groups where prophylactic therapy is desirable.
Because of the complications of chronic headache, prophylactic therapy designed to reduce the frequency and severity of headache is preferred to the repeated use of analgesics or narcotic medicationa'P-!". There are three main forms of prophylactic therapy: pharmacological, biofeedback therapy and behavioural management. Mathew!S and Raskin and Schwartz!" demonstrated the substantial long-term benefits of prophylactic pharmacology, which for reasons of convenience and acceptability will be the mainstay of treatment for the majority of patients. For a small group of well motivated patients, biofeedback methods!" have much to recommend them.
The most widely used prophylactic agents in chronic muscle contraction headache are the benzodiazepines, although many argue that their mode of action is by sedation rather than relaxation of contracted muscle. The risk of habituation and dependence with these drugs is a major drawback. Tricyclic Journal ofthe Royal Society of Medicine Volume80 November 1987 691 antidepressants have proved superior in clinical trials", particularly where depression is a complicating factor. Doses of75 to 125 mg of amitriptyline may be required, with the resulting risk of side effects. We found f1upenthixol to be superior to diazepam as a prophylactic agent, and its pharmacology'':" confers advantages over tricyclics, particularly in promptness of action and freedom from sedation and anticholinergic side effects. It should therefore be considered as the treatment of choice where a prophylactic agent is considered desirable.
